

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

**PRELIMINARY FINANCIAL INFORMATION OF CR SANJIU
FOR THE YEAR ENDED 31 DECEMBER 2025**

On 6 February 2026, CR Sanjiu released its unaudited preliminary financial information for the year ended 31 December 2025.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”) is a company incorporated in the People’s Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.22% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 6 February 2026, CR Sanjiu released its unaudited preliminary financial information for the year ended 31 December 2025 (the “**Reporting Period**”) (the “**CR Sanjiu Preliminary Financial Information**”). Set out below are the key financial information of the CR Sanjiu Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2025 (UNAUDITED)

Unit: RMB ten thousand

Item	The Reporting Period	The corresponding period of previous year	Increase/decrease (%)
Total operating revenue	3,162,947.20	2,761,661.18	14.53%
Operating profit	484,813.57	447,503.09	8.34%
Total profit	486,044.92	459,361.07	5.81%
Net profit attributable to the shareholders of the listed company	342,178.81	336,788.90	1.60%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	315,631.39	311,786.73	1.23%
Basic earnings per share (RMB)	2.06	2.02	1.98%
Weighted average return on net asset (%)	16.08%	17.33%	Lower by 1.25%
	As of the end of the Reporting Period	As of the beginning of the Reporting Period	Increase/decrease (%)
Total assets	5,880,727.61	4,008,197.23	46.72%
Equity attributable to the shareholders of the listed company	2,217,133.60	1,990,311.13	11.40%
Share capital	166,421.79	128,429.87	29.58%
Net assets per share attributable to the shareholders of the listed company (RMB)	13.32	15.50	-14.06%

Notes:

- (1) The above information is based on information from unaudited consolidated financial statements. The financial information set out in the 2025 annual report to be published by CR Sanjiu shall prevail.

- (2) In June 2025, CR Sanjiu completed the implementation of its 2024 profit distribution plan, converting 3 shares for every 10 shares to all of its shareholders using the capital reserve. As of the end of 2025, the net asset value per share attributable to shareholders of the listed company is calculated based on the increased share capital following conversion.
- (3) As of the end of the Reporting Period, CR Sanjiu achieved total assets of RMB58,807,276,100, representing a year-on-year increase of 46.72%, mainly due to the acquisition of Tasly Pharmaceutical Group Co., Ltd. (天士力醫藥集團股份有限公司) during the Reporting Period.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

In 2025, in the face of factors such as a year-on-year decrease in the incidence of respiratory diseases such as influenza and the continuous control of medical insurance fees, CR Sanjiu has anchored its strategic course, adhered to the two-wheel driven “innovation + brand”, and progressed steadily in a complex market environment. CR Sanjiu focused on core treatment areas, expanded R & D pipelines in multiple dimensions, and deeply drove innovation value. CR Sanjiu also cultivated brand advantages, continuously optimized business layout, forged competitive advantages in the whole industry chain, consolidated its leading position in the industry, and move towards the strategic goal of “striving to be a leading enterprise in the industry”.

During the Reporting Period, CR Sanjiu achieved a total operating revenue of RMB31.629 billion, representing a year-on-year increase of 14.53% and a net profit attributable to shareholders of the listed company of RMB3.422 billion, representing a year-on-year increase of 1.60%.

The CR Sanjiu Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by CR Sanjiu in its 2025 annual report shall prevail.

The financial information is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Sanjiu audited annual financial results, please refer to the annual report for the year ended 31 December 2025 to be published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 6 February 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.